CA
Can-Fite BioPharma Ltd.
CANF · AMEX
$2.24 +1.82% (+$0.04)
1M -6.78%
Market Cap $2.93M
P/E Ratio -
Div. Yield -
ROE 195.94%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
57 /100
Fair P/B 0.52x
P/S 7.18x
EV/EBITDA N/A
Growth
15 /100
Declining Book val. growth 7.73%
Rev. growth 20.42%
FCF growth N/A
Profitability
20 /100
Weak Net margin 2,426.67%
Op. margin 2,456.80%
FCF margin 2,210.13%
Quality
1 /100
Poor ROE 195.94%
ROA 104.12%
Asset turnover 0.04x
Debt
69 /100
Low Current ratio 3.46x
Int. coverage -710.72x
Debt/Equity 0.01x
Stability
20 /100
Unstable Rev. volatility 17.71%
EPS volatility 611.96%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CANF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Motti Farbstein
Employees
5
Headquarters
Ramat Gan
Upcoming events
01 APR
Earnings
Upcoming earnings report